Timeline

Eric Prina

Permanent Researcher

12 Jul 2024

event

3rd Drug Discovery & Screening Symposium – “Innovative Therapeutics: Small Molecules and Biologics in Modern Medicine” – an ATC-DDS initiative

15 Nov 2022

publication

Trifloxystrobin blocks the growth of Theileria parasites and is a promising drug to treat Buparvaquone resistance.

10 Feb 2022

project

ANR ELATION: Epigenetic subversion in Leishmania macrophage infection

22 Jun 2020

publication

Dynamic imaging reveals surface exposure of virulent Leishmania amastigotes during pyroptosis of infected macrophages.

20 May 2020

publication

Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations.

20 Feb 2020

publication

SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani.

11 Feb 2020

publication

Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response.

01 Jan 2020

publication

Leishmania amazonensis Subverts the Transcription Factor Landscape in Dendritic Cells to Avoid Inflammasome Activation and Stall Maturation.

24 Jan 2019

publication

Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.

16 Jan 2019

project

International Mixed Unit ‘Inflammation and Leishmania infection’ (IMU-InflaLeish): Exploiting host-pathogen interaction for the discovery of novel anti-microbial drug targets and drug candidates.

16 Jan 2019

project

“Modelling and functional analysis of clonal Evolution in Leishmania – possible role of non-coding RNAs and RNA modification”

23 Dec 2016

publication

Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

22 Sep 2016

publication

Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor

01 May 2016

publication

From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

08 Sep 2015

project

ANR Patho-Methylome – The role of lysine methylation in host-pathogen interactions

07 Sep 2015

project

FP7 Anti-Parasitic Drug Discovery in Epigenetics (A-ParaDDisE)

07 Sep 2015

project

FP7 Targeting the Leishmania kinome for the development of novel anti-parasitic strategies (LeishDrug)

07 Sep 2015

project

ANR TransLeish – Discovery of druggable protein kinases in the protozoan parasite Leishmania donovani using hit compounds identified by phenotypic screening

07 Sep 2015

project

PTR 539 – A multilevel systems approach to elucidate the host-Leishmania interactome and to identify host targets for anti-leishmanial drug discovery

07 Sep 2015

project

PTR 496 – Investigating the reciprocal relationship between macrophage inflammasome activity and intracellular Leishmania infection

11 May 2015

team

Molecular Parasitology and Signaling

31 Oct 2014

publication

Simultaneous multi-parametric analysis of Leishmania and of its hosting mammal cells: A high content imaging-based method enabling sound drug discovery process

01 Jul 2014

publication

Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses.

01 Jan 2014

publication

Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

09 Aug 2012

publication

A little guide for advanced search:

Timeline

3rd Drug Discovery & Screening Symposium – “Innovative Therapeutics: Small Molecules and Biologics in Modern Medicine” – an ATC-DDS initiative

Trifloxystrobin blocks the growth of Theileria parasites and is a promising drug to treat Buparvaquone resistance.

ANR ELATION: Epigenetic subversion in Leishmania macrophage infection

Dynamic imaging reveals surface exposure of virulent Leishmania amastigotes during pyroptosis of infected macrophages.

Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations.

SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani.

Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response.

Leishmania amazonensis Subverts the Transcription Factor Landscape in Dendritic Cells to Avoid Inflammasome Activation and Stall Maturation.

Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.

International Mixed Unit ‘Inflammation and Leishmania infection’ (IMU-InflaLeish): Exploiting host-pathogen interaction for the discovery of novel anti-microbial drug targets and drug candidates.

“Modelling and functional analysis of clonal Evolution in Leishmania – possible role of non-coding RNAs and RNA modification”

Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor

From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

ANR Patho-Methylome – The role of lysine methylation in host-pathogen interactions

FP7 Anti-Parasitic Drug Discovery in Epigenetics (A-ParaDDisE)

FP7 Targeting the Leishmania kinome for the development of novel anti-parasitic strategies (LeishDrug)

ANR TransLeish – Discovery of druggable protein kinases in the protozoan parasite Leishmania donovani using hit compounds identified by phenotypic screening

PTR 539 – A multilevel systems approach to elucidate the host-Leishmania interactome and to identify host targets for anti-leishmanial drug discovery

PTR 496 – Investigating the reciprocal relationship between macrophage inflammasome activity and intracellular Leishmania infection

Molecular Parasitology and Signaling

Simultaneous multi-parametric analysis of Leishmania and of its hosting mammal cells: A high content imaging-based method enabling sound drug discovery process

Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses.

Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms.